CSCX

[setravis]

SPECUTLATIVE PLAY...........

http://stockcharts.com/def/servlet/SC.web?c=DFIB


IRVINE, Calif., June 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- Cardiac Science, Inc. (DFIB, Trade), a leading manufacturer of life-saving automatic public-access defibrillators (AEDs), announced today that it has expanded its multi-year strategic distribution agreements with GE Healthcare, a division of General Electric Company (GE, Trade).

Under the agreements, GE Healthcare will market Cardiac Science's complete line of Powerheart(R)-brand external defibrillators on an exclusive basis to hospitals in the United States and Canada. In addition, GE also confirmed the assignment of the distribution agreements to the new corporate entity being created by the pending merger transaction between Cardiac Science and Quinton Cardiology Systems, Inc. (QUIN, Trade).

The agreements provide GE Healthcare exclusivity in North American hospitals, based on certain annual performance criteria, for Cardiac Science's complete line of defibrillators including Powerheart(R) G3 AEDs, Powerheart(R) CRM(R) and Cardiac Science's new traditional "crash-cart" in-hospital external defibrillator, which is currently pending 510(k) approval by the U.S. Food & Drug Administration and is anticipated to be released for worldwide sale this summer.

Cardiac Science's Chairman and Chief Executive Officer Raymond W. Cohen said, "These agreements confirm that GE Healthcare will market the soon-to-be-released "crash-cart type" defibrillator in North American hospitals under the Powerheart(R)-brand and internationally under the GE Responder(R) brand post our pending merger with Quinton. They also greatly expand our relationship with GE Healthcare by granting GE exclusivity to North American hospitals based on certain performance criteria."

Cohen added, "For the first time, we will soon begin competing for a share of the lucrative traditional in-hospital external defibrillator market where in the United States alone, several hundred million dollars worth of these defibrillators are being purchased each year to replace older models. In addition, we believe GE Healthcare can help us sell AEDs in the emerging U.S. hospital AED market, where AEDs are being deployed in the non-acute sections of the hospital to treat patients and protect visitors and hospital employees who suffer sudden cardiac arrest."

As is the case with the existing line of Cardiac Science Powerheart(R) AEDs, the new traditional "crash-cart" hospital external defibrillator incorporates the Company's patented STAR(R) biphasic technology and RHYTHMx(R) analysis software. The new product will be manufactured by Cardiac Science under the Powerheart(R)-brand for sale by GE Healthcare in North American hospitals, and on a private label basis under the GE Responder(R) brand name for sale by GE Healthcare in Europe, Asia, the Middle East and other international markets.

GE Healthcare first began selling an OEM version of the Cardiac Science- manufactured AEDs internationally in the late 2003. In October 2004, Cardiac Science made its first shipments to GE Healthcare of its G3 PRO AED, designed for medical professionals, under the Responder(R) label.

About Cardiac Science

Cardiac Science, with operations in Orange County, CA, Minneapolis, MN, Manchester, England and Copenhagen, Denmark, develops, manufactures and markets Powerheart(R)-brand automatic public-access defibrillators (AEDs) and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The Company also makes the Powerheart(R) CRM(R), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. In the U.S., Cardiac Science products are sold to corporations, police and fire departments, state and local municipalities, the federal government and schools by its 55-person direct sales force, and certain national and local distributors. Internationally, Cardiac Science products are sold direct in the United Kingdom and by independent distributors in over 60 countries. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies such as Quinton Cardiology Systems, Nihon Kohden (Japan) and GE Healthcare. In 2004, Cardiac Science was recognized by Deloitte & Touche as the 4th fastest growing technology company in North America and as the fastest growing company in Orange County, CA. For more information, please visit http://www.cardiacscience.com or contact Cardiac Science at (949) 797-3800.

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time the company, or its representatives, have made or may make forward looking statements orally or in writing. The words "estimate," "potential," "intended," "expect," "anticipate," "believe," and similar expressions or words are intended to identify forward looking statements. Such forward-looking statements include, but are not limited to the achievement of future revenue growth based on the expanded agreement with GE Healthcare. Cardiac Science has based these forward-looking statements on current expectations, assumptions, estimates and projections. While Cardiac Science believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K for the year ending December 31, 2004, subsequent quarterly filings, and other documents filed by Cardiac Science with the Securities and Exchange Commission. . Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward- looking statements. Cardiac Science does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.


Contact:  Matt Clawson (Investors), or    Michael Gioffredi  
             Len Hall (Media)                Chief Marketing Officer  
             Allen & Caron Inc               Cardiac Science, Inc.  
             (949) 474-4300                  (949) 797 3800  
             [email protected]             [email protected]  
             [email protected]  

SOURCE Cardiac Science, Inc.


Matt Clawson, Investors, [email protected], or Len Hall, Media, [email protected]  
both of Allen & Caron Inc, +1-949-474-4300; Michael Gioffredi, Chief Marketing  
Officer, Cardiac Science, Inc., +1-949-797-3800, [email protected]  

http://www.prnewswire.com  

Copyright (C) 2005 PR Newswire. All rights reserved.

[setravis]

NEW YORK, June 13 (Reuters) - Cardiac Science Inc. (DFIB,Trade) on Monday said it has expanded its multi-year distribution deals with GE Healthcare, a division of General Electric Co. (GE,Trade).

Under the agreements, GE Healthcare will market Cardiac Science's Powerheart brand external defibrillators on an exclusive basis to hospitals in the United States and Canada.

[setravis]

Agreement with GE should finally give this product a
Sales outlet for a great product," and potential cash stream to push
this to higher levels.  I'm in!!!

[saffeysite1]

Merger going thru.  I'm [email protected]

[setravis]

Saffey, what's your take on today's action?

[saffeysite1]

the merger with Quinn is done.  Quinn has no debt and plenty of cash.  Price went down, people want in.  Then comes consolidation.  I would like to see $2.50 in a month.

[setravis]

Below is the Daily Commentary " Buy Confirmed " Posted by American Bulls.Com
To have myself a little fun and test their system,I am going to buy DFIB @ the open tomorrow.
I am going to look for 3 stocks to play this game and buy a $1,000.00 of each.

"CAUTION DO NOT TRY THIS AT HOME"
************************************************************************* 
  DFIB 

CARDIAC SCIENCE CP 
Daily Commentary


Our system posted a BUY   CONFIRMED today. The previous SELL recommendation that was confirmed was made on 06.24.2005 (20) days ago, when the stock price was 1.0100. Since then DFIB has gained 5.94% .
BUY
CONFIRMED


1.0700 
+0.0300  +2.88% 

Candlestick Analysis 
Today's Candlestick Patterns:

White Opening Marubozu 
         

 
           

Today a White Opening Marubozu was formed. This shows that the day opened and then the prices continued to go up all day long without coming below the opening level thus forming a long white body, however prices did not close at the high of the day and thus they created an upper shadow


Stock Quote 
Day's Close 1.0700 
Previous Close  1.0400 
Previous Open  1.0200 
Change  +0.0300 
% Change  +2.88% 
Volume  661,535 
   Stock Activity 
Day's Open  1.0300 
Day's High  1.0800 
Day's Low  1.0300 
50-Day Close M.A.  0.9743 
200-Day Close M.A.  1.4939 
65-Day Volume M.A.  891,065 
   

[setravis]

This little pup is moving up today.
Got some volume coming in, looking good.
May break that 200-day  in the next few days.

[rocket8]

earnings tomorrow

the merger with quinn is big.

so is the deal with GE.

now lets hope for some good results.

[eliteG]

solid play set(applaud)..this wants 1.75-2 bad 

[setravis]

bizjournals.com
Cardiac shareholders set merger vote date
Monday August 1, 2:01 pm ET


Cardiac Science Inc. shareholders will vote on the possible merger of Cardiac and Quinton Cardiology Systems Inc. on Aug. 31.
The meeting will be held at the Stradling Yocca Carson & Rauth law offices in Newport Beach. The proxy statement and prospectus will be mailed out this week to shareholders of record as of July 14.


The new company will be called Cardiac Science Corp.

Under the terms of the agreement, Cardiac (NASDAQ: DFIB - News) shareholders will get 0.10 of a share in the new company for every share of Cardiac, while Quinton (NASDAQ: QUIN - News) shareholders get 0.77 of a share. The company will be 51 percent owned by current Cardiac shareholders and 49 percent owned by holders of Quinton.

Quinton is based in Bothell, Wash., and makes cardiovascular monitoring equipment. Cardiac is based in Irvine and manufactures defibrillators.

Published August 1, 2005 by Los Angeles Business from bizjournals

[setravis]

Had a pullback, up on news out this morning.


****************************************************************
       

MarketWatch
Market Pulse: Cardiac Science up on orders from Army, Nat'l Guard
Monday August 8, 11:58 am ET
By Michael Baron


NEW YORK (MarketWatch) -- Cardiac Science shares gained almost 8% to $1.12 Monday after the Irvine, Calif., maker of automatic external defibrillators said it's received orders worth more than $500,000 from the U.S. Army and National Guard. The company agreed to supply 317 Powerheart G3 systems and related services to four military installations in the U.S.

[setravis]

Press Release Source: Cardiac Science Inc.


U.S. Army and National Guard Purchase $500,000 of Cardiac Science Powerheart(R) AEDs
Monday August 8, 1:30 am ET 
AEDs to Be Deployed at Four Military Facilities Including Nation's Largest Active Duty Armored Post in Fort Hood, Texas


IRVINE, Calif., Aug. 8 /PRNewswire-FirstCall/ -- Cardiac Science Inc. (Nasdaq: DFIB - News), a leading manufacturer of life-saving automatic external defibrillators (AEDs) and provider of comprehensive AED/CPR training and AED program management services, announced today that it has received orders for 317 Powerheart® G3 AEDs to be delivered in this quarter along with AED/CPR training and program management services valued at more than $500,000 from four major military installations in the U.S.
The military branches awarding contracts to Cardiac Science include the Birmingham, Alabama-based U.S. Army 81st Regional Support Command, the U.S. Army Corps of Engineers, Louisville District; the Maine National Guard and Fort Hood, Texas, the largest active duty armored post in the country. Fort Hood supports two full armored divisions and covers a total of 339 square miles.

Along with providing AEDs to the U.S. Army 81st Regional Support Command, Cardiac Science will also train more than 2,600 of its personnel at numerous locations in Alabama, Florida, Georgia, Mississippi, Kentucky, North Carolina, South Carolina, and Tennessee. The Army unit provides command and control and direct support services for more than 30,000 soldiers.

"Our Powerheart AEDs and program services continue to be the leading choice of the U.S. military, which has become a rapidly expanding market for AEDs and AED training," said Raymond W. Cohen, Cardiac Science Chairman and CEO. "Clearly these military units have the ability to select any AED manufacturer to supply products, but consistently choose Cardiac Science and the Powerheart AED because of our robust self-testing technology, overall product reliability and our ability to provide turnkey AED/CPR training and AED program management services. We plan to continue to build on these established relationships with the U.S. military with a view toward capturing an increasingly larger share of this important market segment."

[setravis]

Active in the pre-market
+ 28.43%.......Volume @ 514,290

End of the day chart Thursday 25 August

[setravis]

Press Release Source: Cardiac Science Inc.


Cardiac Science Receives Approval From the Japanese Ministry of Health to Market Its Biphasic Version AEDs in Japan
Thursday August 25, 4:00 pm ET


IRVINE, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Cardiac Science Inc. (Nasdaq: DFIB - News), a leading U.S. manufacturer of life-saving automatic public-access defibrillators (AEDs), announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market a biphasic version of the Company's AEDs in Japan. The biphasic AED product, a private-labeled OEM version of Cardiac Science's flagship Powerheart® AED, will be marketed in Japan under the CardioLife® brand name by Nihon Kohden Corporation, (Tokyo: JP: 6849), Japan's largest medical device manufacturer.



"This is a major milestone for Cardiac Science, one that will allow us to begin realizing significant sales in Japan as we enter the fourth quarter of 2005 and into 2006 and beyond," said Raymond W. Cohen, Cardiac Science Chairman and CEO.

"This biphasic submission has been under review by Japanese regulators for over two years, well beyond our initial expectation. As AED demand has grown in Japan, so has the demand for biphasic version AEDs. This regulatory delay has allowed one of our competitors with an approved biphasic version to make up ground in this market. As a result, our 2005 shipments to Japan dropped off substantially from strong second half 2004 levels. We are now able to get aggressively back on the playing field and continue making inroads into this important market. As mentioned in our recent investor conference call, Nihon Kohden reports that substantial demand exists for our biphasic AED product. The product is now ready for shipment and we are confident that with our biphasic version AED will allow us to regain our previous momentum," said Cohen.

Tokyo-based Nihon Kohden, which has approximately 650 sales people in Japan, began selling Cardiac Science-manufactured AEDs in the second quarter of 2002 and quickly became the AED market share leader in Japan by selling approximately 10,000 Cardiac Science-manufactured AEDs to Japanese physicians and hospitals.

In 2003 Japan's MHLW approved the use of AEDs by non-medical persons marking a significant shift in the Japanese ministry's view toward the use of AEDs, which formerly could only be legally used by physicians, paramedics and trained flight attendants in airplanes. Now any Japanese citizen or organization can deploy an AED after undergoing a course in AED operation.

About the Japanese AED Market

According to published market analysis, the Japanese AED market has the potential to be approximately 60,000 units per year by 2010 roughly 20 percent the size of the combined U.S. and European markets. Current buyers of AEDs in Japan include medical and dental clinics, hospitals, fitness centers, airports and airlines.

Potential AED users in Japan include thousands of commercial buildings and government facilities as well as approximately 90,000 physician offices, 53,000 police, fire and emergency vehicles, 41,000 schools, 2,000 golf courses, Japan's extensive railway system and consumers.

About Cardiac Science's Patented STAR® Biphasic AED Technology

Among other things, AEDs employ technology that allows for an electric shock to be delivered to the heart using either a monophasic or biphasic defibrillation shock waveform. That is, current can travel in a single direction throughout the shock (monophasic), or the direction of the current can be reversed partway through the shock (biphasic). Studies have proven that biphasic waveforms are efficacious as compared to traditional monophasic waveforms using similar energy levels and may decrease damage to the heart.

Cardiac Science's patented STAR® biphasic 'self-tracking active response' waveform customizes the defibrillation therapy for each patient by measuring each patient's ability to conduct electricity (impedance) and automatically customizing the waveform for that specific patient by varying duration, voltage and energy in order to optimize external defibrillation efficacy. Subsequent shocks progressively escalate to higher levels if additional shocks are needed to convert a sudden cardiac arrest victim to a normal rhythm.

STAR biphasic has been proven in published multi-center clinical studies to have a first shock success rate of 100% using average energy levels of approximately 200 Joules. In clinical studies conducted using out-of-hospital data, STAR biphasic was able to successful restore normal patient rhythm in less than 55 seconds using only 2 shocks on average.

About Nihon Kohden

Nihon Kohden Corporation, (Tokyo: JP: 6849), Japan's largest medical device manufacturer manufactures a variety of diagnostic medical devices including patient monitoring systems, electrocardiograms, electroencephalograms, cardiac monitors and external defibrillators.

About Cardiac Science

Cardiac Science develops, manufactures and markets a complete line of Powerheart® brand, automatic public-access defibrillators (AEDs), and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare. For more information please visit www.cardiacscience.com or call 1.949.797.3800.

This press release includes forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Cardiac Science has based these forward-looking statements on the current expectations, assumptions, estimates and projections. While Cardiac Science believes the regulatory approval in Japan to be a benefit to the company and that it will allow sales in that region to improve in the coming periods , these expectations, assumptions, estimates and projections, while reasonable, are forward-looking statements and are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. Certain factors, including those discussed in Cardiac Sciences' Annual Report on Form 10-K for the year ended December 31, 2004, under the heading "Risk Factors," may cause the actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.


     Contact:  Matt Clawson (Investors)    Michael D. Gioffredi
               Len Hall (Media)            Chief Marketing Officer
               Allen & Caron Inc           Cardiac Science, Inc.
               (949) 474-4300              (949) 797-3800
               [email protected]         [email protected]
               [email protected]




--------------------------------------------------------------------------------
Source: Cardiac Science Inc.